Home Tags HER2-positive

Tag: HER2-positive

Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced...

Following initiation of pivotal phase II studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase II study in colorectal...

Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...

Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...

Updated Analysis from Ongoing Phase I Trial of DS-8201 Confirms Significant...

About one in five breast cancers overexpress HER2, a tyrosine kinase receptor growth-promoting protein found on the surface of some cancer cells, which is...

Mersana and Takeda Expand Partnership to Advance Development of Fleximer® based...

Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new, expanded, strategic partnership.  Under the terms of the agreement,  Takeda...

Preclinical Data Confirms Therapeutic Potential of SYD985 in Patients with Low...

Preclinical data of SYD985, presented by Synthon Biopharmaceutical's Gijs Verheijden during the 37th Annual San Antonio Breast Cancer Symposium (SABCS), being held at The...

Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...

Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.

The Next Advancements in Cancer Drug Development: Antibody-Drug Conjugates

The annual meeting of the American Society of Clinical Oncology (ASCO) conference held June 1-5, 2012 in Chicago, IL offered a wealth of new...

Monoclonal Antibodies (mAbs), the “Magic Bullets” of Cancer Care, Are Now...

Monoclonal Antibodies (mAbs), once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way,...

Antibody-drug Conjugate for MBC Highlights Importance of Personalised Approach to Cancer...

Results of the first randomized phase II study, known as TDM4450g, in patients with previously untreated HER2-positive metastatic breast cancer (mBC) were presented today at...

Investigational Antibody-Drug Conjugate, Shows Encouraging Results in Women With Highly Advanced...

Results of a Phase II study of trastuzumab (Herceptin®, Genentech) in combination with DM1 (T-DM1), an investigational HER2 antibody-drug conjugate being developed by Genentech,...

FEATURED RESOURCES